Genentech To Use Upside From Avastin For Incremental R&D, SG&A Spend
The oncologic generated sales of $38.1 mil. during the first five weeks on the market. Genentech has raised its earnings guidance to 20% to 25% for the year.
The oncologic generated sales of $38.1 mil. during the first five weeks on the market. Genentech has raised its earnings guidance to 20% to 25% for the year.